Women who suffer greater menopause symptoms are more likely to experience memory and thinking problems as they age, research has suggested.Experts found that women who recalled a heavier burden of ...

New milestone achieved in Astellas T-cell engager collaboration: In February 2025, Astellas advanced the second program to ...

In February 2025, Atea appointed Arthur S. Kirsch to the Company's Board of Directors. Mr. Kirsch has decades of experience ...

Clinical data on track for Q2 2025 in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLCExpansion of investigator sponsored “window of opportunity” trial into newly diagnosed ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Tris Pharma’s first-in-class oral dual-NMR agonist achieved its primary endpoint in the ALLEVIATE-2 study by demonstrating a ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced presentation of preclinical data supporting the advancement of ...

Thus, with low price valuations by the investors, these stocks will continue to offer returns that surpass the returns from ...

Mind Medicine (MindMed) Inc. ( NASDAQ: MNMD) Q4 2024 Earnings Conference Call March 6, 2025 8:00 AM ET Stephanie Fagan - Chief Corporate Affairs Officer Rob Barrow - CEO Dan Karlin - CMO ...

ANAB remains risky despite new clinical data and partnerships; past successes haven't been replicated, and management's transparency issues raise concerns.

Biodexa Pharmaceuticals (BDRX) announced the appointment of Precision for Medicine as the clinical research organization, CRO, to conduct the ...

A detailed review of a 6-month clinical trial further reinforces strong experimental evidence that a ketogenic diet may offer ...